Clinical trials: sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Follow-up in Early and Locally Advanced Breast Cancer Patients
A cross-sectional follow-up study of Early and Locally Advanced Breast Cancer patients after primary treatment.
- Trial name
- NCT03859453
- Where
- 28 sites in Belgium, France and 8 more
- Volunteers
- 830 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer Stage II, Breast Cancer Stage III
Adjuvant Palbociclib in Elderly Patients With Breast Cancer
Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients…
- Trial name
- Appalaches (NCT03609047)
- Testing
- Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide
- Where
- 73 sites in Belgium, France and 7 more
- Volunteers
- 366 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer
RATIONALE: Adjuvant therapy given after surgery for early breast cancer may cause infertility. Assessing young women's attitudes and feelings about the risk of infertility may help improve the ability to plan effective treatment.
- Conditions
- Breast Cancer, Psychosocial Effects of Cancer and Its Treatment, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues
- Trial name
- NCT00062400
- Testing
- psychosocial assessment and care
- Where
- 27 sites in Belgium, Chile and 13 more
- Volunteers
- 385 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Rationale: Gathering medical information and tumor samples from patients with male breast cancer may help doctors learn more about the disease.
- Trial name
- NCT01101425
- Where
- 93 sites in United States, Belgium and 14 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
AML (Acute Myeloid Leukemia)
FLT3-ITD Targeted Therapy in Fit AML Patients
This international, multicenter, randomized (1:1), open-label phase II/III trial will evaluate the efficacy and safety of gilteritinib combined with azacitidine and venetoclax (experimental arm) versus standard "7+3" induction…
- Trial name
- FIT-AML (NCT07425808)
- Testing
- Gilteritinib, Venetoclax, Azacitidine (AZA)
- Volunteers
- 230 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioma, Glioneuronal Tumor
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on…
- Conditions
- Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors
- Trial name
- NCT05259605
- Testing
- Observational
- Where
- 42 sites in Austria, Belgium and 10 more
- Volunteers
- 1,650 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Astrocytoma, Grade III, Glioblastoma
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
This is a three parallel cohort, open-labeled, non-randomized, multicenter study. All three cohorts will enroll independently.
- Trial name
- STEAM (NCT03224104)
- Testing
- TG02, Radiation Therapy, Temozolomide
- Where
- 10 sites in Austria, France and 3 more
- Volunteers
- 71 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Medulloblastoma
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
Medulloblastoma is a rare brain malignancy, mainly affecting children. Treatment of this rapidly growing tumor begins with maximal surgical removal plus radiation and chemotherapy. Treatment toxicity is high.
- Trial name
- PersoMed-I (NCT04402073)
- Testing
- Sonidegib, Cisplatin, Lomustine
- Where
- 50 sites in Australia, Austria and 6 more
- Volunteers
- 20 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
This is an open label non-comparative controlled randomized phase II study. The experimental arm is the group receiving ODM-201. The group receiving androgen-deprivation therapy (ADT) is included as an internal control.
- Trial name
- NCT02972060
- Testing
- ODM-201, ADT
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 61 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Phase III Radium 223 mCRPC-PEACE III
The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) by investigator assessment compared to enzalutamide single agent in…
- Trial name
- PEACE III (NCT02194842)
- Testing
- Ra223, Enzalutamide
- Where
- 64 sites in Belgium, Brazil and 10 more
- Volunteers
- 446 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce…
- Trial name
- NCT05974774
- Testing
- iMAB, cMAB
- Where
- 9 sites in Denmark, France and 1 more
- Volunteers
- 1,600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Pleural Mesothelioma
Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
This is a multicenter, randomized, 1:1, double blinded phase II trial. Patients with unresectable malignant pleural mesothelioma (MPM) will be randomized between arm A: nintedanib and arm B:placebo
- Trial name
- NEMO (NCT02863055)
- Testing
- Nintedanib
- Where
- 9 sites in Belgium, Italy and 1 more
- Volunteers
- 37 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease.
- Conditions
- Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma, Any Stage of Any Thymic Malignancy
- Trial name
- SPECTAlung (NCT02214134)
- Testing
- Tumour markers testing
- Where
- 18 sites in Belgium, France and 7 more
- Volunteers
- 539 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
Oropharyngeal Squamous Cell Carcinoma (OPSCC) arises in the soft palate, tonsils, base of tongue, pharyngeal wall, and the vallecula. Most of the patients with early stage OPSCC are usually cured.
- Conditions
- Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- Best Of (NCT02984410)
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Trans Oral Surgery (TOS)
- Where
- 32 sites in Belgium, France and 6 more
- Volunteers
- 112 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00005584
- Testing
- bleomycin sulfate, ABVD regimen, BEACOPP regimen
- Where
- 121 sites in Belgium, France and 8 more
- Volunteers
- 1,649 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with combination chemotherapy may kill more tumor cells.
- Trial name
- NCT00002462
- Testing
- bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride
- Where
- 56 sites in Belgium, Egypt and 7 more
- Volunteers
- 615 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00379041
- Testing
- bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride
- Volunteers
- 1,158 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00049595
- Testing
- bleomycin sulfate, filgrastim, pegfilgrastim
- Where
- 140 sites in Australia, Belgium and 11 more
- Volunteers
- 552 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Unresectable Stage III Melanoma, Stage IV Melanoma
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
This is a multicenter, 2-arm open-label, randomized comparative phase II study. The objective of this trial is to prospectively evaluate whether a sequential approach with an induction period of 12 weeks with encorafenib +…
- Trial name
- EBIN (NCT03235245)
- Testing
- Nivolumab + Ipilimumab, Encorafenib + Binimetinib
- Where
- 38 sites in Denmark, Finland and 7 more
- Volunteers
- 271 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Uterine Sarcoma
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
This study aims to investigate a drug called Cabozantinib which belongs to a family of drugs that have effects on tumour growth, blood supply, invasion and spread.
- Trial name
- NCT01979393
- Testing
- Cabozantinib
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 58 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC